Immuron Limited Submits IND Application to FDA for IMM529 to Treat and Prevent Clostridioides difficile Infection
I'm PortAI, I can summarize articles.
Immuron Limited has submitted an IND application to the FDA for IMM-529, aimed at treating and preventing Clostridioides difficile infection (CDI). The company plans to start a Phase 2 clinical trial in the first half of 2026, targeting patients with both first episode and recurrent CDI. No funding announcements were made. This news is generated by Public Technologies and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments